Affordable cancer care needs more than price caps

The government’s decision to regulate trade margins on non-scheduled cancer drugs is a response to an urgent public-health concern. In recent years, new therapies have offered hope for cancer patients. At the same time, unaffordable drugs are known to be a major cause for patients delaying treatment, skipping doses or even stopping medication. According to the National Pharmaceutical Pricing Authority, intermediaries between manufacturers and patients — stockists, distributors, hospital pharmacies, and wholesale agents — add an average profit mark-up of around 170 per cent to the prices of these medicines. Now, the government has capped the seller’s profit at 30 per cent of the MRP. The intervention’s litmus test will be in making treatment more accessible.

Regulating trade margins is not the same as controlling prices set by manufacturers. The cap does not apply to the price at which companies sell medicines to distributors or hospitals. If the initial price is too high, the treatment may remain unaffordable even after the trade margin limit comes into force. Patented drugs face little competition from generic alternatives, giving manufacturers greater control over their prices. The price trajectory of medicines already subject to caps underlines the limitations of this approach. The monthly cost of ribociclib reportedly rose from Rs 58,000 to Rs 78,000, despite the restrictions placed on profits on the breast cancer drug in 2019. Another challenge is the use of artificial discounts to distort the apparent market price. Manufacturers may offer steep discounts on a small number of units to select corporate hospitals while selling most of their stock at much higher prices. This could make it difficult for regulators to determine the medicine’s actual market price. Trade margin regulation must therefore be backed by closer scrutiny of manufacturers’ prices and transparent reporting of sales and discounts.

Overall Analysis

The editorial examines the issue of affordability of cancer treatment in India and argues that regulating the profit margins of medicine sellers alone cannot ensure affordable healthcare. It acknowledges the government’s decision to cap trade margins on non-scheduled cancer drugs as an important step towards reducing the financial burden on patients. However, the author emphasises that the effectiveness of this intervention will depend on whether it actually makes cancer treatment accessible to ordinary people.

The editorial begins by highlighting the growing importance of new cancer therapies, which have provided hope to patients but remain financially out of reach for many. High medicine prices often force patients to delay treatment, skip prescribed doses or discontinue medication altogether. The author draws attention to the substantial profit margins charged by intermediaries such as distributors, stockists and hospital pharmacies. By introducing a 30 per cent cap on sellers’ profit margins, the government intends to control excessive mark-ups and reduce the final cost of medicines. However, the author makes it clear that the real measure of success is improved accessibility, not merely the introduction of a price regulation policy.

In the second part, the editorial explains an important distinction between regulating trade margins and controlling manufacturers’ prices. While the government has restricted the profits earned by intermediaries, it has not directly controlled the prices at which pharmaceutical companies initially sell their medicines. This creates a major limitation because even a reduced profit margin cannot make a medicine affordable if its original price is excessively high. The problem becomes more serious in the case of patented medicines, where the absence of generic competition allows manufacturers greater freedom in determining prices.

To strengthen this argument, the author provides the example of ribociclib, a breast cancer drug whose monthly cost reportedly increased from ₹58,000 to ₹78,000 despite existing restrictions on profit margins. This example demonstrates that controlling intermediary profits does not necessarily prevent medicine prices from increasing.

The editorial further highlights the possibility of artificial discounts, through which manufacturers may offer substantial discounts on limited quantities of medicines to selected corporate hospitals while selling the majority of their stock at much higher prices. Such practices can create a misleading picture of actual market prices and make regulatory monitoring difficult.

Finally, the author argues that trade margin regulation must be accompanied by stricter monitoring of manufacturers’ pricing practices and transparent disclosure of sales and discounts. The underlying message is that affordable cancer care requires a comprehensive approach rather than dependence on a single regulatory measure.

From a language perspective, the editorial uses economic and public-health terminology to explain a policy issue. It employs cause-and-effect reasoning, numerical evidence and real-life examples to establish its argument. Expressions such as “litmus test”, “price trajectory” and “distort the apparent market price” make the writing analytical and precise.

2. Important Vocabulary (5)

3. Conclusion & Tone

Conclusion:

The editorial argues that controlling trade margins on cancer medicines is a welcome policy intervention, but it cannot independently solve the problem of expensive cancer treatment. Since pharmaceutical manufacturers retain considerable control over the initial prices of patented medicines, the government must also strengthen price monitoring, ensure transparency and regulate unfair pricing practices. The ultimate objective should be to make life-saving cancer treatment financially accessible to all sections of society.

Tone: Analytical, critical and reform-oriented.

Key Learning for Students: The editorial teaches an important distinction between controlling intermediary profit margins and controlling the actual price of a product. It also demonstrates how numerical evidence, examples and cause-and-effect reasoning can be used to evaluate the effectiveness of a government policy.